Short Courses and Special Courses

SC36 - The Updated WHO Classification of Myeloid Neoplasms: A Practical Approach to Genetically-Defined and Not-So-Well Defined Entities

Thursday, March 22, 2018 - 8:00 am - 11:30 am
This Short Course session includes up to a half-hour break.

Session Credits:

3 CME and 3 SAMs


Attilio Orazi, MD, FRCPath, Weill Cornell Medical College, New York, NY
Daniel A. Arber, MD, University of Chicago, Chicago, IL
Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA

Course Description

The World Health Organization (WHO) is implementing a revised Classification of Tumors of the Hematopoietic and Lymphoid Tissues, scheduled for release in 2017. For the group of the myeloid neoplasms, several modifications in terminologies and diagnostic guidelines have been included in the updated classification. The knowledge of this new classification scheme and how it should be applied in a clinical diagnostic setting is of great importance. The careful integration of recent molecular discoveries provides unique challenges for hematopathologists diagnosing these neoplasms. Despite recent advances, careful morphologic evaluation and clinical correlation remain essential components of well-integrated evidence-based diagnosis, which is a key factor in achieving optimal clinical management of these neoplasms. This course will enhance the diagnostic skills of the pathologists, especially hematopathologists, who often deal with these challenging neoplasms. The course, directed by three of the authors of the upcoming “blue book”, will comprehensively educate pathologists on the new classification. It will use clinical cases to explain in a practical manner the rationale of the changes made in various diagnostic entities. The participant should expect to benefit by achieving a better uniformity of interpretation and enhanced and up-to-date diagnostic skills.

Learning Objectives

Upon completion of this educational activity, the learner will be able to:

  • Provide an overview of the molecular genetics of these tumors, including advances in their pathogenetic and potentially therapeutic role
  • Discuss the minimal amount of clinical information required to diagnose a given case
  • Determine what can be said "upfront" and what must wait. Understand a proper "sequence" in function of the clinical needs


Continuing Medical Education and Maintenance of Certification

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.

Physicians can earn a maximum of 3 SAM credit hours.


Return to 2018 Annual Meeting Short Course Page


view more